Clear cell carcinoma of the ovary - A remarkable case

被引:3
作者
Giblin, J
Fanucchi, MP
McGuire, WP
机构
[1] Emory Clin, Atlanta, GA 30322 USA
[2] Mercy Med Ctr, Gynecol Oncol Ctr, Baltimore, MD USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2001年 / 24卷 / 01期
关键词
ovarian carcinoma; clear cell histology; topotecan;
D O I
10.1097/00000421-200102000-00020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clear cell carcinoma of the ovary is uncommon, and there are few reports of successful long-term therapy, In this case report, a previously healthy preadolescent presented with clear cell carcinoma of the ovary. After progressing through two regimens of chemotherapy, she was given topotecan, which arrested the disease. Nearly 3 years later, she continues to lead a near-normal life as a high school student. Our treatment plan is to continue to administer this therapy at monthly intervals until relapse. Although the achievement of stable disease with topotecan is frequently observed in patients relapsing with epithelial ovarian cancer, durable stable disease in clear cell carcinoma of the ovary is unusual. Treatment- and long-term maintenance therapy- with topotecan may be an option in such patients. In this cast, the lack of cumulative toxicities allows the patient tu maintain her usual daily activities.
引用
收藏
页码:99 / 100
页数:2
相关论文
共 5 条
[1]   Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study [J].
Creemers, GJ ;
Bolis, G ;
Gore, M ;
Scarfone, G ;
Lacave, AJ ;
Guastalla, JP ;
Despax, R ;
Favalli, G ;
Kreinberg, R ;
VanBelle, S ;
Hudson, I ;
Verweij, J ;
Huinink, WWT .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) :3056-3061
[2]  
GORDON A, 1996, P AN M AM SOC CLIN, V15, P282
[3]  
HOCHSTER H, 1996, P AN M AM SOC CLIN, V15, P285
[4]   Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma [J].
Kudelka, AP ;
Tresukosol, D ;
Edwards, CL ;
Freedman, RS ;
Levenback, C ;
Chantarawiroj, P ;
deLeon, CG ;
Kim, EE ;
Madden, T ;
Wallin, B ;
Hord, M ;
Verschraegen, C ;
Raber, M ;
Kavanagh, JJ .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1552-1557
[5]   Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study [J].
McGuire, WP ;
Blessing, JA ;
Bookman, MA ;
Lentz, SS ;
Dunton, CJ .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (05) :1062-1067